Compare Stocks: LONA, ACOG, ZNTL, and SBTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACOG Alpha Cognition	$8.34 +0.4%	$8.96	$4.50 ▼ $10.14	$181.63M	2.32	99,799 shs	134,714 shs
LONA Athira Pharma	$4.84 -2.6%	$6.34	$2.21 ▼ $14.21	$45.47M	2.11	503,491 shs	33,791 shs
SBTX Silverback Therapeutics	$4.03 -6.7%	$4.84	$2.80 ▼ $8.97	$145.31M	0.6	337,931 shs	1.52 million shs
ZNTL Zentalis Pharmaceuticals	$2.21 -8.3%	$3.13	$1.21 ▼ $6.95	$158.40M	1.93	1.47 million shs	947,069 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACOG Alpha Cognition	0.00%	+1.83%	-2.68%	+5.57%	+20.87%
LONA Athira Pharma	0.00%	-6.92%	-3.01%	-34.51%	+483,999,900.00%
SBTX Silverback Therapeutics	-6.71%	+0.25%	-3.59%	-32.15%	-59.29%
ZNTL Zentalis Pharmaceuticals	0.00%	+3.76%	-19.64%	-48.96%	+35.58%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACOG Alpha Cognition	$8.34 +0.4%	$8.96	$4.50 ▼ $10.14	$181.63M	2.32	99,799 shs	134,714 shs
LONA Athira Pharma	$4.84 -2.6%	$6.34	$2.21 ▼ $14.21	$45.47M	2.11	503,491 shs	33,791 shs
SBTX Silverback Therapeutics	$4.03 -6.7%	$4.84	$2.80 ▼ $8.97	$145.31M	0.6	337,931 shs	1.52 million shs
ZNTL Zentalis Pharmaceuticals	$2.21 -8.3%	$3.13	$1.21 ▼ $6.95	$158.40M	1.93	1.47 million shs	947,069 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACOG Alpha Cognition	0.00%	+1.83%	-2.68%	+5.57%	+20.87%
LONA Athira Pharma	0.00%	-6.92%	-3.01%	-34.51%	+483,999,900.00%
SBTX Silverback Therapeutics	-6.71%	+0.25%	-3.59%	-32.15%	-59.29%
ZNTL Zentalis Pharmaceuticals	0.00%	+3.76%	-19.64%	-48.96%	+35.58%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACOG Alpha Cognition	3.00	Buy	$18.00	115.83% Upside
LONA Athira Pharma	2.50	Moderate Buy	$17.33	258.13% Upside
SBTX Silverback Therapeutics	0.00	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	2.64	Moderate Buy	$7.50	239.37% Upside

Current Analyst Ratings Breakdown

Latest LONA, ACOG, ZNTL, and SBTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/19/2026	ZNTL Zentalis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$10.00
10/14/2026	ZNTL Zentalis Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
10/5/2026	ZNTL Zentalis Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Market Perform ➝ Outperform	$4.00 ➝ $8.00
10/2/2026	ZNTL Zentalis Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/30/2026	ZNTL Zentalis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Equal Weight	$5.00
9/16/2026	ZNTL Zentalis Pharmaceuticals	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
8/20/2026	ACOG Alpha Cognition	B. Riley Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$21.00
8/19/2026	LONA Athira Pharma	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$16.00 ➝ $15.00
8/17/2026	ACOG Alpha Cognition	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$18.00 ➝ $20.00
8/17/2026	LONA Athira Pharma	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Market Outperform	$18.00 ➝ $17.00
8/14/2026	ACOG Alpha Cognition	Craig Hallum Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$17.00

(Data available from 10/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACOG Alpha Cognition	$15.26M	11.90	N/A	N/A	$2.88 per share	2.90
LONA Athira Pharma	N/A	N/A	N/A	N/A	$2.98 per share	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	$7.41 per share	N/A
ZNTL Zentalis Pharmaceuticals	$67.43M	2.35	N/A	N/A	$2.99 per share	0.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACOG Alpha Cognition	-$20.67M	-$1.10	N/A	N/A	N/A	-153.61%	-54.60%	-43.47%	11/12/2026 (Estimated)
LONA Athira Pharma	-$105.61M	-$4.21	N/A	N/A	N/A	N/A	-411.58%	-225.73%	N/A
SBTX Silverback Therapeutics	-$89.48M	-$2.42	N/A	N/A	N/A	N/A	-29.62%	-28.20%	N/A
ZNTL Zentalis Pharmaceuticals	-$137.06M	-$1.95	N/A	N/A	N/A	N/A	-70.18%	-51.46%	11/10/2026 (Estimated)

Latest LONA, ACOG, ZNTL, and SBTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	ACOG Alpha Cognition	-$0.33	N/A	N/A	N/A	$7.04 million	N/A
11/10/2026	Q3 2026	ZNTL Zentalis Pharmaceuticals	-$0.58	N/A	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	LONA Athira Pharma	-$0.60	-$0.80	-$0.20	-$0.80	N/A	N/A
8/13/2026	Q2 2026	ACOG Alpha Cognition	-$0.3921	-$0.40	-$0.0079	-$0.40	$4.38 million	$6.00 million
8/6/2026	Q2 2026	ZNTL Zentalis Pharmaceuticals	-$0.49	-$0.59	-$0.10	-$0.59	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACOG Alpha Cognition	N/A	N/A	N/A	N/A	N/A
LONA Athira Pharma	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACOG Alpha Cognition	N/A	9.03	8.04
LONA Athira Pharma	N/A	7.01	7.01
SBTX Silverback Therapeutics	N/A	67.87	67.87
ZNTL Zentalis Pharmaceuticals	N/A	4.82	4.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACOG Alpha Cognition	N/A
LONA Athira Pharma	57.12%
SBTX Silverback Therapeutics	74.89%
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ACOG Alpha Cognition	8.60%
LONA Athira Pharma	25.73%
SBTX Silverback Therapeutics	34.40%
ZNTL Zentalis Pharmaceuticals	3.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACOG Alpha Cognition	71	21.78 million	19.91 million	Optionable
LONA Athira Pharma	19	9.39 million	6.98 million	No Data
SBTX Silverback Therapeutics	83	36.06 million	23.65 million	Not Optionable
ZNTL Zentalis Pharmaceuticals	106	71.67 million	68.95 million	Optionable

LONA, ACOG, ZNTL, and SBTX Headlines

Recent News About These Companies

Zentalis Pharmaceuticals Announces Median Overall Survival Data In Cyclin E1-Positive Platinum-Resistant Ovarian Cancer From DENALI Part 1b

October 24 at 8:33 AM | marketscreener.comM

Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ...

October 23 at 12:30 PM | finance.yahoo.com

Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026

October 23 at 10:15 AM | globenewswire.com

Zentalis published survival data for Zentalis Pharmaceuticals stock

October 21, 2026 | ad-hoc-news.deA

Zentalis Reports Interim OS Rates Of 15 Months In Cyclin-E1 PROC Patients Treated With Azenosertib

October 19, 2026 | rttnews.com

Zentalis Highlights Interim Survival Data From DENALI Part 1b Study Of Azenosertib In PROC

October 19, 2026 | rttnews.com

Zentalis rises as lead asset extends survival in mid-stage trial for ovarian cancer

October 19, 2026 | msn.com

HC Wainwright Reaffirms Buy Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

October 19, 2026 | americanbankingnews.com

Zentalis Pharmaceuticals' (ZNTL) Buy Rating Reiterated at HC Wainwright

October 19, 2026 | marketbeat.com

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

October 18, 2026 | globenewswire.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Upgraded at Jefferies Financial Group

October 17, 2026 | americanbankingnews.com

Leerink raised its target to USD 8 for Zentalis Pharmaceuticals stock

October 15, 2026 | ad-hoc-news.deA

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Lifted to Strong-Buy by Jefferies Financial Group

October 15, 2026 | marketbeat.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) & Aquestive Therapeutics (NASDAQ:AQST) Financial Comparison

October 14, 2026 | americanbankingnews.com

Zentalis Pharmaceuticals stock gains 10.32 percent after Leerink upgrade

October 6, 2026 | ad-hoc-news.deA

Zentalis Pharmaceuticals Shares Rise After Leerink Upgrade

October 6, 2026 | finance.yahoo.com

Zentalis Pharmaceuticals stock heads toward October cancer data

October 5, 2026 | ad-hoc-news.deA

Leerink Upgrades Zentalis Pharmaceuticals to Outperform From Market Perform, Price Target is $8

October 5, 2026 | finance.yahoo.com

Zentalis Pharmaceuticals (ZNTL) Gets a Hold from Wells Fargo

October 5, 2026 | theglobeandmail.com

Zentalis Pharmaceuticals Shares Rise After Leerink Assumes Coverage With Outperform Rating

October 5, 2026 | finance.yahoo.com

Zentalis Pharmaceuticals' (ZNTL) "Outperform" Rating Reiterated at Leerink Partners

October 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA, ACOG, ZNTL, and SBTX Company Descriptions

Alpha Cognition NASDAQ:ACOG

$8.34 +0.03 (+0.36%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$8.36 +0.02 (+0.24%)

As of 10/23/2026 07:30 PM Eastern

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Athira Pharma NASDAQ:LONA

$4.84 -0.13 (-2.62%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$4.87 +0.03 (+0.62%)

As of 10/23/2026 05:43 PM Eastern

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Silverback Therapeutics NASDAQ:SBTX

$4.03 -0.29 (-6.71%)

As of 10/23/2026

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$2.21 -0.20 (-8.30%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$2.20 0.00 (-0.23%)

As of 10/23/2026 07:37 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LONA, ACOG, ZNTL, and SBTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LONA, ACOG, ZNTL, and SBTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LONA, ACOG, ZNTL, and SBTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA, ACOG, ZNTL, and SBTX Company Descriptions

Alpha Cognition NASDAQ:ACOG

Athira Pharma NASDAQ:LONA

Silverback Therapeutics NASDAQ:SBTX

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LONA, ACOG, ZNTL, and SBTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LONA, ACOG, ZNTL, and SBTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LONA, ACOG, ZNTL, and SBTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA, ACOG, ZNTL, and SBTX Company Descriptions

Alpha Cognition NASDAQ:ACOG

Athira Pharma NASDAQ:LONA

Silverback Therapeutics NASDAQ:SBTX

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools